Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

Bibliography

• Altamura AC, Buoli M, Albano A, Dell'Osso B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol 2010;25:172-9
   PubMed Web of Science ®Google Scholar
• Kujanpää T, Ylisaukko-Oja T, Jokelainen J, et al. Comparative cost analysis of generalized anxiety disorder and major depressive disorder patients in secondary care from a national hospital registry in Finland. Nord J Psychiatry 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2011;14:697-710
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 2011;12:2457-67
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 2013;9:883-92
   PubMed Web of Science ®Google Scholar
• Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder. Can J Psychiatry 2012;57:470-8
   PubMed Web of Science ®Google Scholar
• Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013;28:7-20
   PubMed Web of Science ®Google Scholar
• Altamura AC, Serati M, Buoli M, Dell'Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 2011;26:201-5
   PubMed Web of Science ®Google Scholar
• Buoli M, Dell'osso B, Bosi MF, Altamura C. Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64:612-19
   PubMed Web of Science ®Google Scholar
• Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21:S703-9
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc) 2007;43(9):601-10
   PubMed Web of Science ®Google Scholar
• Howland RH. Agomelatine: a novel atypical antidepressant. J Psychosoc Nurs Ment Health Serv 2007;45:13-17
   Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42
   PubMed Web of Science ®Google Scholar
• Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. J Clin Psychopharmacol 2012;32:487-91
   PubMed Web of Science ®Google Scholar
• Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 2013;28:12-19
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Corruble E, Hale A, et al. A pooled analysis of six momth comparative efficacy and tolerability in four randomized clinical trias: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 2013;18:163-70
   PubMed Web of Science ®Google Scholar
• Papp ML, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006;17:9-18
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012;73:1002-8
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8:287-304
   PubMed Web of Science ®Google Scholar
• Ying SW, Rusak B, Delagrange P, et al. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996;296:33
   PubMed Web of Science ®Google Scholar
• Popoli M. Agomelatine. Innovative pharmacological approach in depression. CNS Drugs 2009;23:27-34
   PubMed Web of Science ®Google Scholar
• Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28(3):303-7
   PubMed Web of Science ®Google Scholar
• Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther 2006;28:1540-55
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;177:448-58
   PubMed Web of Science ®Google Scholar
• Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31
   PubMed Web of Science ®Google Scholar
• Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
   PubMed Web of Science ®Google Scholar
• Martin JR, Ballard TM, Higgins GA. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 2002;71:615-25
   PubMed Web of Science ®Google Scholar
• Loiseau F, Le Bihan C, Hamon M, Thiébot MH. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol 2006;16:417-28
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Evaluation of Medicines for Human Use CHMP Assessment Report for Valdoxan, 2009
   Google Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008;23:396-402
   PubMed Web of Science ®Google Scholar
• Servier Laboratories Ltd. Valdoxan (agomelatine). Summary of Product Characteristics. 2013
   Google Scholar
• De Berardis D, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci 2013;14:12458-83
   PubMed Web of Science ®Google Scholar
• Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008;42:1822-31
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Agomelatine: a novel antidepressant. Innov Clin Neurosci 2011;8:10-14
   Google Scholar
• Heun R, Ahokas A, Boyer P, et al. Agomelatine Study Group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 2013;74:587-94
   PubMed Web of Science ®Google Scholar
• Niederhofer H. Efficacy of duloxetine and agomelatine does not exceed that of other antidepressants in patients with autistic disorder: preliminary results in 3 patients. Prim Care Companion CNS Disord 2011;13:1
   Google Scholar
• Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009;5:563-76
   PubMed Web of Science ®Google Scholar
• Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012;26:39-67
   PubMed Web of Science ®Google Scholar
• Buoli M, Caldiroli A, Caletti E, et al. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother 2013;14:175-84
   PubMed Web of Science ®Google Scholar
• Fornaro M. Agomelatine in the treatment of panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:286-7
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-20
   PubMed Web of Science ®Google Scholar
• Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol 2013;28:151-9
   PubMed Web of Science ®Google Scholar
• Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J 2012;53:e228-30
   PubMed Web of Science ®Google Scholar
• Morera-Fumero AL, Abreu-Gonzalez P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J Clin Psychopharmacol 2010;30:739-41
   PubMed Web of Science ®Google Scholar
• Servier Laboratories Ltd. Direct Healthcare Professional Communication on the risk of hepatotoxicity with agomelatine. 2012
   Google Scholar
• Štuhec M. Agomelatine-induced hepatotoxicity. Wien Klin Wochenschr 2013;125:225-6
   PubMed Web of Science ®Google Scholar
• Gruz F, Raffa S, Santucci C, et al. Agomelatine: fulminant liver failure in a patient with fatty liver. Gastroenterol Hepatol 2014;37(2):92-4
   PubMed Web of Science ®Google Scholar
• Laux G, VIVALDI Study Group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 2012;45:284-91
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20
   PubMed Web of Science ®Google Scholar
• Karakus E, Halici Z, Albayrak A, et al. Agomelatine: an antidepressant with new potent hepatoprotective effects on paracetamol-induced liver damage in rats. Hum Exp Toxicol 2013;32:846-57
   PubMed Web of Science ®Google Scholar
• Viejo Sacha MG, De Ambrosi B, Muñoz C, et al. Two cases of delirium with agomelatine therapy. Ann Clin Psychiatry 2013;25(1):67-8
   PubMed Web of Science ®Google Scholar
• Kozian R, Syrbe G. QTc prolongation during treatment with agomelatine. Psychiatr Prax 2010;37:405-7
   PubMed Web of Science ®Google Scholar
• Imboden C, Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry 2012;45(4):162-3
   PubMed Web of Science ®Google Scholar
• Both C, Kojda G, Lange-Asschenfeldt C. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Expert Rev Neurother 2014;14(1):29-38
   PubMed Web of Science ®Google Scholar
• Endicott J, Svedsäter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat 2012;8:301-11
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Arici C, Dobrea C, et al. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol 2012;27:310-13
   PubMed Web of Science ®Google Scholar
• Agomelatine: AGO 178, AGO178, S 20098. Drugs R D 2008;9(3):177-83
   PubMedGoogle Scholar